Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Nilotinib is a highly selective Bcr-Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). Nilotinib and dasatinib, a multi-targeted kinase inhibitor also approved for second line therapy in CML, have different patterns of kinase selectivity, pharmacokinetics, and cell uptake...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Giles, Francis J., Abruzzese, Elisabetta, Rosti, Gianantonio, Kim, Dong-Wook, Bhatia, Ravi, Bosly, Andre, Goldberg, Stuart, Kam, Grace L.S., Jagasia, Madan, Mendrek, Wlodzimierz, Fischer, Thomas, Facon, Thierry, Dünzinger, Ulrich, Marin, David, Shou, Yaping, Gallagher, Neil J., Larson, Richard A., Mahon, Francois-Xavier, Baccarani, Michele, Cortes, Jorge, Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3078756/
https://ncbi.nlm.nih.gov/pubmed/20520639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.110
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares